Clinical Trials
Blinded Sample Size Reestimation in Non‐Inferiority Trials with Binary Endpoints
Abstract
Sample size calculations in the planning of clinical trials depend on good estimates of the model parameters involved. When the estimates of these parameters have a high degree of uncertainty attached to them, it is advantageous to reestimate the sample size after an internal pilot study. For non‐inferiority trials with binary outcome we compare the performance of Type I error rate and power between fixed‐size designs and designs with sample size reestimation. The latter design shows itself to be effective in correcting sample size and power of the tests when misspecification of nuisance parameters occurs with the former design. (© 2007 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim)
Citing Literature
Number of times cited according to CrossRef: 14
- Volkmar Falk, Tim Friede, Noninferiority trials: What's clinically (ir)relevant?, The Journal of Thoracic and Cardiovascular Surgery, 10.1016/j.jtcvs.2020.03.168, (2020).
- Yongqiang Tang, Score confidence intervals and sample sizes for stratified comparisons of binomial proportions, Statistics in Medicine, 10.1002/sim.8674, 39, 24, (3427-3457), (2020).
- Pascal Urwyler, Maria Boesing, Kristin Abig, Marco Cattaneo, Thomas Dieterle, Andreas Zeller, Herbert Bachler, Stefan Markun, Oliver Senn, Christoph Merlo, Stefan Essig, Elke Ullmer, Jonas Rutishauser, Macé M Schuurmans, Joerg Daniel Leuppi, Reduction of corticosteroid use in outpatient treatment of exacerbated COPD - Study protocol for a randomized, double-blind, non-inferiority study, (The RECUT-trial), Trials, 10.1186/s13063-019-3856-8, 20, 1, (2019).
- Jan Deprest, Anne Debeer, Lennart Van der Veeken, Karel Allegaert, Liesbeth Lewi, Luc De Catte, Congenital Diaphragmatic Hernia: In Utero Treatment Today and Tomorrow , Fetal Therapy, 10.1017/9781108564434, (503-511), (2019).
- Nicole Gilgen, Ahmed Farah, Bruno Scheller, Marc‐Alexander Ohlow, Norman Mangner, Daniel Weilenmann, Jochen Wöhrle, Peiman Jamshidi, Gregor Leibundgut, Sven Möbius‐Winkler, Robert Zweiker, Florian Krackhardt, Christian Butter, Leonhard Bruch, Christoph Kaiser, Andreas Hoffmann, Peter Rickenbacher, Christian Mueller, Frank‐Peter Stephan, Michael Coslovsky, Raban Jeger, Drug‐coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET‐SMALL 2, Clinical Cardiology, 10.1002/clc.22942, 41, 5, (569-575), (2018).
- Raban V Jeger, Ahmed Farah, Marc-Alexander Ohlow, Norman Mangner, Sven Möbius-Winkler, Gregor Leibundgut, Daniel Weilenmann, Jochen Wöhrle, Stefan Richter, Matthias Schreiber, Felix Mahfoud, Axel Linke, Frank-Peter Stephan, Christian Mueller, Peter Rickenbacher, Michael Coslovsky, Nicole Gilgen, Stefan Osswald, Christoph Kaiser, Bruno Scheller, Peter Buser, Michael Kühne, Michael Zellweger, Christian Sticherling, Bastian Wein, Raphael Twerenbold, Gregor Fahrni, Björn Plicht, Berthold Struck, Ismet Önal, Bodo Cremers, Yvonne Clever, Sebastian Ewen, Stephan Schirmer, Michael Böhm, Andreas Wagner, Bernward Lauer, Georg Stachel, Robert Höllriegel, Ephraim Winzer, Hans Rickli, Peter Ammann, Philipp Haager, Lukas Trachsel, Lucas Joerg, Dominique Nüssli, Hans Roelli, Micha Maeder, Franziska Rohner, Sinisa Markovic, Rima Paliskyte, Dominik Buckert, Belal Awad, Paul Erne, Peiman Jamshidi, Florim Cuculi, Ioannis Kapos, Stefan Toggweiler, Florian Riede, Tudor Pörner, Karsten Lenk, Michel Noutsias, Ralf Surber, Gudrun Dannberg, Markus Franz, Sylvia Otto, Robert Zweiker, Ella NIederl, Sabine Perl, Burkert Pieske, Albrecht Schmidt, Olev Luha, Dirk Von Lewinski, Florian Krackhardt, Behrouz Kherad, Timo Jerichow, Christian Butter, Michael Neuss, Grit Tambor, Frank Hölschermann, Leonhard Bruch, Sebastian Winkler, Corinna Lenz, Mirko Seidel, Boris Keweloh, Alexandra Röttgen, Steffen Bohl, Alexander Wolf, Andreas Hoffmann, Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial, The Lancet, 10.1016/S0140-6736(18)31719-7, 392, 10150, (849-856), (2018).
- T. Friede, M. Kieser, Sample Size Reassessment in Non-inferiority Trials, Methods of Information in Medicine, 10.3414/ME09-01-0063, 50, 03, (237-243), (2018).
- Anja Sander, Geraldine Rauch, Meinhard Kieser, Blinded sample size recalculation in clinical trials with binary composite endpoints, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2016.1198371, 27, 4, (705-715), (2016).
- Kazunari Murakami, Yuuichi Sakurai, Madoka Shiino, Nobuo Funao, Akira Nishimura, Masahiro Asaka, Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study , Gut, 10.1136/gutjnl-2015-311304, 65, 9, (1439-1446), (2016).
- Andrew Montgomery Hartley, A Bayesian adaptive blinded sample size adjustment method for risk differences, Pharmaceutical Statistics, 10.1002/pst.1708, 14, 6, (488-514), (2015).
- Hans‐Joachim Helms, Norbert Benda, Jörg Zinserling, Thomas Kneib, Tim Friede, Spline‐based procedures for dose‐finding studies with active control, Statistics in Medicine, 10.1002/sim.6320, 34, 2, (232-248), (2014).
- H.-J. Helms, N. Benda, T. Friede, Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2014.920343, 25, 5, (939-957), (2014).
- Monika Pobiruchin, Meinhard Kieser, Sample Size Calculation and Blinded Sample Size Recalculation in Clinical Trials Where the Treatment Effect is Measured by the Relative Risk, Communications in Statistics - Simulation and Computation, 10.1080/03610918.2012.674595, 42, 7, (1643-1653), (2013).
- Tim Friede, Holger Stammer, Blinded Sample Size Recalculation in Noninferiority Trials: A Case Study in Dermatology, Drug Information Journal, 10.1177/009286151004400507, 44, 5, (599-607), (2010).
